Press Room

News / Oct 04, 2016

Hovione is the API Supplier of the Year

Hovione receives Global the Generics & Biosimilars Award 2016 in the category of API Supplier of the Year.

During 2016 CPhI Worldwide, Hovione was recognised as the API Supplier of the Year with a Global Generics & Biosimilars Award. This award recognises Hovione for its achievements over the preceding 12 months and was judged by a panel of industry experts.

The Global Generics & Biosimilars Awards 2016 ceremony is presented by the Generics bulletin and it was held in Barcelona on 4 October 2016.

Hovione is the API Supplier of the Year | Hovione

 

 

 

 

 

 

 

 

Find more about Hovione's Off-Patent API products

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026